Media Advisory: Journal of Clinical Oncology publishes outcomes from the practice-changing DREAMseq trial in patients with advanced melanoma

After years of research, many exciting and effective new combination treatments exist for patients with advanced melanoma. As a result, patients and their physicians often find themselves with multiple treatment options but few answers to questions surrounding how and when to use these new approaches. In addition, melanoma can be highly aggressive, and existing treatments often stop working. Final results are now available for the randomized phase 3 trial DREAMseq (EA6134) for melanoma patients with a BRAF V600 tumor gene mutation.

DREAMseq showed that starting treatment with immunotherapy (nivolumab and ipilimumab), followed by targeted therapy (dabrafenib and trametinib) if there is disease progression, is the preferred treatment approach. "I think the standard of care should immediately change because these are FDA-approved regimens," said lead researcher Michael B. Atkins, MD (Georgetown University Lombardy Comprehensive Cancer Center). Atkins MD. J Clin Oncol. September 2022

###